ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

A National Survey of Valganciclovir Dosing Strategies in Pediatric Solid Organ Transplant Recipients

S. Shaikh, N. Panek, J. Park.

MedStar Georgetown University Hospital, Washington DC
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Michigan Medicine, Ann Arbor.

Meeting: 2018 American Transplant Congress

Abstract number: C354

Keywords: Cytomeglovirus, Infection

Session Information

Session Name: Poster Session C: Transplant Infectious Diseases

Session Type: Poster Session

Date: Monday, June 4, 2018

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

Objective: The FDA-approved pediatric indication of valganciclovir (VGCV) is limited to cytomegalovirus (CMV) prophylaxis in heart and kidney transplants. The recommended regimen is a daily dose calculated by 7 x BSA x CrCl [using a modified Schwartz formula (k x ht/Scr), max CrCl of 150 ml/min, and Scr measured by the Jaffe method] for a duration of 100 and 200 days, respectively. Data are scarce on appropriate VGCV dose and duration in pediatric solid organ transplant (SOT) recipients. This study aimed to describe the current VGCV dosing strategies used for CMV prophylaxis and treatment among pediatric SOT centers.

Methods: In November 2017, a survey of pharmacists was conducted through the Internet to assess VGCV dosing and duration strategies for CMV prophylaxis and treatment at pediatric SOT centers in the U.S.

Results: Of 54 centers that perform pediatric SOTs, 23 (42.6%) responded to the survey. Responses were for kidney (n=19), liver (n=15), heart (n=8), small bowel (n=3), and lung (n=1). Thirteen centers (59.1%) reported calculating VGCV dose for CMV prophylaxis using 7 x BSA x CrCl, with 8 centers (61.5%) using a max CrCl of 150 ml/min. Seven (53.8%) used the modified Schwartz formula, 5 (38.5%) used the bedside Schwartz formula (0.413 x ht/Scr), and one center used the modified Schwartz formula for heart and the bedside Schwartz formula for kidney. Only 8 centers (34.8%) reported using the Jaffe method to measure Scr, while a majority (65.2%) were unsure of the assay type used. Others based VGCV dosing on weight (13-16 mg/kg/day) or BSA (900 or 450 mg/1.73 m2/day). The reported duration of VGCV for CMV prophylaxis ranged from 3-12 months. For the treatment of CMV, VGCV dosing also differed across centers, with a majority (43.5%) using 7 x BSA x CrCl.

Conclusion: VGCV dosing strategies for CMV prophylaxis and treatment differed significantly across U.S. pediatric SOT centers and by organ type. Less than two thirds of responding centers utilized the FDA-approved dosing regimen, with various methods of CrCl calculation and Scr measurement. The duration of CMV prophylaxis reported deviated frequently from the FDA-label. Studies evaluating clinical outcomes associated with different VCGV dosing and duration strategies are warranted to determine the most appropriate VGCV regimen for CMV prophylaxis and treatment in pediatric SOT recipients.

CITATION INFORMATION: Shaikh S., Panek N., Park J. A National Survey of Valganciclovir Dosing Strategies in Pediatric Solid Organ Transplant Recipients Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Shaikh S, Panek N, Park J. A National Survey of Valganciclovir Dosing Strategies in Pediatric Solid Organ Transplant Recipients [abstract]. https://atcmeetingabstracts.com/abstract/a-national-survey-of-valganciclovir-dosing-strategies-in-pediatric-solid-organ-transplant-recipients/. Accessed June 1, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences